Cell & Gene Therapy Logistics: Precision Operations for Next-Gen Pharma

This article from Marken highlights the specialized operational requirements for transporting and managing cell and gene therapies, which represent a growing frontier in biopharmaceutical supply chains. Unlike traditional pharmaceuticals, cell and gene therapies demand extraordinary precision in temperature control, timing, and handling protocols—making them among the most challenging products to move through global logistics networks. The piece underscores why dedicated expertise, infrastructure, and processes are non-negotiable for this high-value, often time-sensitive segment.

For supply chain professionals, this signals a critical inflection point: as cell and gene therapies scale from pilot programs to commercial deployment, logistics providers and manufacturers must invest in specialized capabilities or risk compromising therapeutic efficacy and patient outcomes. The financial stakes are extraordinarily high—a single temperature excursion or handling error can render a therapy worthless, leading to product loss, regulatory scrutiny, and patient harm. Organizations lacking specialized cold-chain expertise, real-time monitoring, and validated processes will face competitive disadvantages.

The strategic implication is clear: supply chain teams must now evaluate their readiness for advanced therapy logistics. This includes assessing third-party logistics partners' qualifications, upgrading temperature monitoring systems, implementing chain-of-custody protocols, and training personnel on biologics handling. Companies entering the advanced therapy space cannot treat this as a commodity logistics problem—it requires a fundamentally different operational approach.